DexCom ($DXCM) Litigation Over Device Compliance and Regulatory Disclosures Case
$DXCM investors filed a claim against DexCom for misrepresenting the safety and accuracy of its G7 glucose monitoring device and failing to disclose unauthorized product changes that triggered regulatory action and patient harm.
After a series of disclosures from the FDA, a whistleblower report, and a scathing downgrade citing patient injuries and even deaths, $DXCM fell 20.6% from $85.44 on March 7, 2025, to $67.45 on September 19, 2025.
$DXCM investors can join this case to be notified about potential recovery.
Between July 26, 2024, and September 17, 2025, DexCom promoted its G7 continuous glucose monitoring (CGM) system as a next-generation device, highlighting its FDA-cleared status and enhanced performance. The company described design changes as minor upgrades and pointed to increasing sales and broader adoption. Public disclosures did not reference any significant regulatory or product issues during this period.
On March 7, 2025, DexCom disclosed that it had received an FDA warning letter related to unapproved modifications made to the G6 and G7 CGM systems. The FDA later stated that these changes resulted in the devices being classified as “adulterated,” and noted that certain modifications could impact insulin dosing accuracy. Following the disclosure and subsequent clarification, DexCom’s stock declined approximately 13% over several trading sessions in March 2025.
On September 8, 2025, an analyst downgrade cited increasing questions around G7 performance. One week later, on September 18, an investigative report referenced FDA documents and former employees in raising concerns about safety events and customer experiences with the G7. That same week, DexCom’s stock fell an additional 11.76%, closing at $67.45 on September 19, 2025.
It made unauthorized and undisclosed changes to its G7 product, compromising safety.
It misrepresented the accuracy and regulatory status of its flagship CGM device.
It exposed investors to reputational, legal, and regulatory risks through misleading statements.
Investors argue DexCom misled the market about the G7’s reliability and compliance, leading to sharp losses when the truth surfaced.